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A B S T R A C T
Objective: To analyze the costs of the surgical treatment of cutaneous carcinomas held in the Plastic Surgery service at a university
hospital in patients of the Unified Health System (SUS). Methods: we included seventy-one patients recorded their demographic
and operation data. For analysis of direct costs we considered the period of patient hospitalization, including human and material
costs. Results: The average equipment cost per procedure was R$ 324.70, and the mean cost of hospital service, according to the
table of SUS, was R$ 193.66. Thus, we obtained an average total cost of R$ 518.36 per procedure. However, the average amount
refunded by the SUS per hospital procedure was R$ 429.19. Conclusion: Surgical treatment of cutaneous carcinomas generated
for the hospital an average deficit of R$ 89.16 per procedure.
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Study conducted at the Sapucai Valley University – UNIVÁS, in collaboration with the Post-Graduation Program in Translational Surgery,
UNIFESP-EPM.
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INTRODUCTION
Skin carcinomas are the most common malignancies inhumans 1. Mainly due to the high number of cases,
among all types of cancer in Australia in 2001, it was the
one generating more spending on treatment, costing the
health care system of this country US$ 262 million, or
approximately US$ 14.60  per capita 2.
In the United States, the annual expenditure on
the treatment of non- melanoma skin cancer amounts to
US$ 650 million for the whole population and type of cancer
was the fifth to generate more costs 3. Skin carcinomas
also have increasing economic impact in Europe 4. In
Germany, hospitalizations due to them in 2003 cost US$
281 million 5.
In Brazil, the National Cancer Institute
(INCA) estimates that in 2012 and in 2013, the non-
melanoma types of skin cancer will have been the
most frequent in the Brazil ian population, with
134,000 new cases, 63,000 in men and 71,000  in
women6. Despite being the most frequent neoplasia
in Brazil in both genders, it is considered that these
figures are underestimated because many suspicious
lesions may be removed without diagnosis or even
be misdiagnosed 7.
The health care of the population is a problem
faced by many countries. Currently, the need for studies to
assess the economic impact of health actions has grown 8.
The economic evaluation is important for decision-making
regarding the allocation of resources, seeking greater
efficiency in their use 9.
Whereas public and private funds for health care
are limited, cost analysis and evaluation of results becomes
an indispensable part in the development of health policies 10.
The aim of this study was to analyze the costs of
the surgical treatment of cutaneous carcinoma, held in a
plastic surgery service at a university hospital, in patients of
the public Unified Health System (SUS).
METHODS
We conducted a primary, analytical,
observational study. The project was approved by the Ethics
in Research Committee of the Sapucaí Valley University
(protocol 260 / 09).
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The series consisted of 71 patients undergoing
in-hospital surgical treatment of skin carcinomas by the
Unified Health System, at the Department of Plastic Surgery
of the Hospital of the Sapucaí Valley University, from August
2009 to August 2010.
Patients included were the ones diagnosed with
skin cancer confirmed by pathological examination who
underwent surgical treatment by the staff of Plastic Surgery
at the surgical center of a university hospital. No patients
were included if without a confirmed diagnosis, undergoing
treatment in outpatient basis or treated by other services.
The total amount paid by the health system to
the hospital per patient was calculated and included hospi-
tal services, doctors, daily fees and accompanying
pathological examinations. The direct cost is the amount
spent by the health system specifically for the treatment;
to calculate it the amounts paid by pathological
examinations and daily companions are subtracted from
the total value. The cost to the hospital was also calculated
per patient, including spending on medical fees, with
materials and medicines, and also the fee of hospital service
provided, which corresponds to the value reimbursed by
the SUS to the hospital, a value predefined by the SUS
table, which varies depending on the procedure performed.
The cost of the surgical procedure, including
human and material costs, was evaluated using the TASY
system software for health management. Data on
demographics, clinical status and related to the surgical
procedure were collected from medical records.
For analysis of results, we used descriptive
statistics, with mean, median and standard deviation.
RESULTS
The distribution of the 71 included patients in
relation to gender was similar, with a slightly higher
frequency of women (52% of cases). Ages ranged from 40
to 90 years (69.8 years) and as for the color the most
prevalent was white, in 94.4%.
The most common histological type was basal
cell carcinoma. As a whole, 87 tumors were resected and
had the diagnosis confirmed, of which 68 were located in
the head, six on the neck, nine in the upper limbs, four in
the lower limbs, and one in the breast.
The mostly used type of anesthesia was local
anesthesia with sedation. Length of hospital stay was one
day to 40.8% of patients, two days for 25.4% and three to
33.8%. Resection followed by grafting and resection
followed by Z-plasty were the most frequently used
techniques, both in 26.8% of procedures, followed by simple
resection in 15% of cases.
To obtain the total cost of the procedure, the
values of medical fees, pathological tests, materials,
medicines and daily values   of accompanying family
members were added. Medical fees were paid according
to the type of operation, ranging from R$ 28.20 to
R$ 344.25, mean R$ 115.77. The amount reimbursed by
SUS for pathological examinations per patient ranged from
R$ 48.00 to R$ 336.00, mean R$ 122.35.
According to information contained in the
operating records, spending on medicines and materials
ranged from R$ 43.06 to R$ 428.38 per patient, with an
average of R$ 97.92. Only patients over 60 years of age
have the right to by accompanied by a family member, R$
4.00  being the value paid by the SUS for their daily stay. In
this study, 32 patients required a companion, totaling 43
such daily fees.
The sum of these costs led to an average total
cost of R$ 324.70 per procedure. Hospital service fees were
not included. It represents the value that the institution
should receive according to the table of SUS, excluding the
aforementioned fees to cover costs of cleaning staff, nursing,
electricity, water, rent, equipment, etc.. This rate changes
according to the type of procedure and its complexity,
ranging from R$ 97.28 to R$ 437.96, with an average of
R$ 193.66.
Adding the average total cost per procedure
(R$ 324.70) to the average rate of hospital services provided
by the SUS (R$ 193.66), we have average total amount of
R$ 518.36 per procedure. However, the average amount
paid by SUS to the hospital during the study period was
R$ 429.19 per procedure. Therefore, the hospital had an
average deficit of R$ 89.16 per patient (Table 1).
DISCUSSION
It’s common sense that skin cancer generates
direct and indirect costs for governments, health plans and
a significant number of patients 11-19.
Despite the importance of analyzing the financial
impact of the treatment of skin carcinomas, there are no
detailed estimates of the costs to the national health care
system, since information about their diagnosis and
treatment are not systematically recorded. Economic
evaluation, as well as strict records of incidence, location,
histological type and sociodemographics of the more
frequently affected population are important for decision
making regarding the allocation of resources, seeking
greater efficiency in their use 9.
Once diagnosed, the treatment options for
cutaneous tumors include both surgical and non surgical
procedures. Regardless of the approach used, the goals
are the complete extirpation of the tumor, preserving the
maximum amount of normal tissue and minimal cosmetic
damage. The choice of treatment depends on location,
age, comorbidities and risk factors of tumor recurrence 20,21.
Surgical treatment in particular depends on the
location and size of the lesion, the characteristics of the
skin, the shape of the lesion, the surgeon’s familiarity with
certain techniques, as well as their creativity in planning
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the surgery, and spending grow according to the degree of
disease, operating time, length of hospital stay, need of
companion, comorbidities and occurrence of complications
22,23.
The surgical treatment of skin cancer is a relevant
problem in the management of health sector and requires
considerable financial demand for its realization 5. Public
hospitals face huge administrative challenge to treat these
patients because, depending on the case, the balance is
negative after the procedure. To avoid this impasse, among
others, it is necessary to readjust the values   reimbursed by
the SUS based on a consistent model with actual
expenditures and educate professionals involved so there
is no waste and thorough record of the materials used is
carried out.
Actions of primary prevention through protection
against solar radiation are effective and inexpensive, and
should be part of education in workplaces, schools and
health facilities programs. Moreover, as the disease is
characterized by the cumulative effects of exposure to risk
factors, the campaigns should have their focus on children,
adolescents and their parents 23.
Secondary prevention through careful
dermatological examination should also be performed. The
skin is the organ of easy access to self-examination and
medical examination and allows the diagnosis of cancer in
the early stages. As the risk of disease increases with age,
80% of all these cancers are diagnosed from 55 years on.
Thus, efforts should be concentrated in this age group, so
that the diagnosis is done at early stages and require less
complex treatments, which will reflect in lower morbidity
and lower costs per patient 18.
Improving the current situation and administration
of funds goes along  the inevitable path of building a data
network that enables real socio-demographic analysis of
the epidemiology of skin carcinoma and of treatment costs
through a model more compatible with the country’s reality,
and strategies for reversing underpricing 3.
Thus, as duly registered new data become
available, it becomes feasible to evaluate trends in
management, different options and costs resulting from the
treatment. This information would provide greater
effectiveness of efforts to decrease costs associated with
the treatment of this disease, which is an increasingly
important public health problem 24.
In conclusion, the surgical treatment of cutaneous
carcinomas treated by SUS generated for the hospital an
average deficit of R$ 89.16 per procedure.
Table 1 – Mean values   in R$ per patient.
R $
CASH IN Amount paid by the SUS by procedure 429.19
CASH OUT Medical Fees 115.77
Pathological Examinations 122.35
Daily companion 5.41
Materials and medications 97.92
Total Cost 324.70
BALANCE What’s left (what the SUS paid minus total cost) 104.50
What should be received as hospital fees, according to the SUS table 193.66
Balance (what the SUS paid less than what the hospital should receive) - 89.16
R E S U M O
Objetivo: analisar os custos do tratamento cirúrgico de carcinomas cutâneos, realizado em serviço de Cirurgia Plástica de hospital
universitário, em pacientes do Sistema Único de Saúde (SUS). Métodos: setenta e um pacientes foram incluídos e registrados seus
dados sociodemográficos e da operação. Para análise de custos diretos foi considerado o período de internação do paciente,
incluindo custos materiais e humanos.  Resultados: o custo material médio por procedimento foi R$.324,70, e o valor médio da taxa
de serviço hospitalar, segundo a tabela do SUS, foi R$.193,66. Com isso, obteve-se um custo total médio de R$.518,36 por
procedimento. Entretanto, o valor médio repassado pelo SUS ao hospital por procedimento foi R$.429,19. Conclusão: o tratamen-
to cirúrgico dos carcinomas cutâneos gerou para o hospital, um déficit médio de R$.89,16 reais por procedimento.
Descritores: Neoplasias cutâneas. Carcinoma. Cirurgia plástica. Honorários e preços. Sistema único de saúde.
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